The diagnosis of a pancreatic cyst as mucinous or high-risk dictates the need for follow-up or surgery.
INTRODUCTION
Pancreatic cysts are common findings on abdominal imaging studies, with reported incidence ranging from 2.6% to 13.5% in asymptomatic patients and increasing in prevalence with older age. [1] [2] [3] These cysts pose a diagnostic and therapeutic dilemma; because, although some cysts may have overt features of malignancy on imaging, the vast majority do not, nor do they often have clearly diagnostic features of cyst type. [1] [2] [3] [4] Despite the malignant potential of some cysts, the morbidity associated with pancreatic surgery raises the level of diagnostic certainty needed before surgical intervention can be considered. As such, endoscopic ultrasound (EUS) and cytologic sampling by fine-needle aspiration (EUS-FNA) has emerged as a favored modality for evaluating pancreatic cysts and subsequently triaging patients to clinical follow-up or surgery. [5] [6] [7] Management decisions are based on mucinous versus nonmucinous etiology and high-risk versus low-risk lesions. [6] [7] [8] Nonmucinous cysts, such as pseudocysts and serous cystadenomas with characteristic imaging features, receive conservative, observational follow-up, because these cysts do not progress to malignancy. Patients who have mucinous cysts without high-risk features (such as branch-duct intraductal papillary mucinous neoplasms [IPMNs] without an enhancing mural nodule that lack high-grade dysplasia) receive periodic imaging studies to exclude malignant progression. A mucinous etiology may be determined by several factors on cytology, including thick, colloid-like extracellular mucin and mucinous epithelium [9] [10] [11] [12] [13] (Fig. 1A,B) , as well as elevated levels of cyst fluid carcinoembryonic antigen (CEA >192 ng/mL) 14, 15 . Genetic studies, particularly those demonstrating an activating guanine nucleotide-binding protein (GNAS) or v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, have begun to gain acceptance as markers of mucinous differentiation, particularly for IPMNs. 4, [16] [17] [18] Cysts at high risk for malignancy are identified by high-risk imaging features (main duct dilatation > 10 mm, enhancing mural nodule, or pancreatic head cyst causing obstructive jaundice) or high-risk cytology (high-grade atypia [HGA] or carcinoma) (Fig. 1B,C) . 6 Because CEA levels do not correlate with grade and most cysts do not have high-risk imaging, cytology is currently the primary means of assessing the risk of malignancy.
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To better standardize reporting of pancreaticobiliary cytopathology, particularly for pancreatic cysts, the Papanicolaou Society of Cytopathology proposed a set of guidelines in 2015. 19 However, despite these efforts, pancreaticobiliary cytology remains a challenge: Sensitivity and specificity were previously reported as 43.4% and 96.2%, respectively, for the identification of mucinous cysts on cytology alone, but they increase to 80.9% and 97.7%, respectively, when CEA analysis is included. 15 The identification of HGA is also difficult, with a previously reported j value of 0.45 (up to 0.74 between experienced observers). 11 Because of this challenge, additional ancillary studies are needed to support the diagnostic impression and prognostic value of cytology. In this study, we evaluate the added value of routine molecular analysis of aspirated pancreatic cyst fluid (PCF) to the diagnostic and risk profile provided by the current means of clinical assessment using cytology and biochemical testing (CEA and amylase) (Fig. 1) . Figure 1 . Examples of mucinous cytology and grades of atypia on cyst cytologic specimens are shown, including (A) low-grade (upper left) mucinous epithelium with hyperchromatic but small, polarized nuclei and intermediate-grade (middle right), mucinous atypia with nucleomegaly, nuclear membrane irregularity, and coarser chromatin; (B) high-grade atypia in a background of acellular mucin in which the cells have a dramatically higher nuclear-to-cytoplasmic ratio, nuclear irregularity is increased, and polarization is lost; and (C) adenocarcinoma with significant nucleomegaly, prominent nucleoli, anisonucleosis, loss of organization, and tumor diathesis. Cyst fluids were processed using a standardized routine method of PCF triage. 20 An aliquot of fresh vortexed, neat PCF (at least 0.3 mL) was removed for molecular analysis, and the remaining cyst fluid was spun down with the cell button processed as a cytospin for routine Papanicolaou staining. The supernatant was sent to the in-house chemistry laboratory for CEA and amylase testing. Molecular testing of PCF was performed using an anchored multiplex polymerase chain reaction (PCR), next-generation sequencing (NGS) platform, as described elsewhere. 21 This protocol sequences areas of numerous exons of 39 known oncogenes to detect commonly identified variants. The variant data are reviewed by molecular pathologists, and variants determined to be functionally significant are reported. For the purposes of this study, only these clinically significant variants were analyzed. Mucinous cysts were defined as those with any of the following parameters: 1) PCF was grossly mucinous on examination (thick, viscous, white, opaque, or sticky); 2) mucinous epithelium or thick, acellular mucin was present on microscopy; 3) the CEA level was >192 ng/mL; and 4) KRAS or GNAS variants were identified. Cysts were defined as nonmucinous if all 4 of these parameters defining a mucinous cyst were absent.
MATERIALS AND METHODS
For the outcome analysis, patients were categorized into 3 groups: nonmucinous cysts, IPMNs (premalignant), and cancer (IPMN with high-grade dysplasia or adenocarcinoma). An adequate diagnosis was established based either on clinicopathologic findings, which included either surgical resection, FNA biopsy, or core biopsy with specific findings (such as pancreatic adenocarcinoma in a liver metastasis), or on unequivocal clinical findings. Clinical bases for the diagnosis of malignancy consisted of specific imaging findings, such as a high-risk pancreatic cyst by imaging with a solid component revealing the invasion of local structures, encasement of vessels, or with evidence of metastatic disease and no evidence or history of other malignancy. A diagnosis of IPMN by imaging required strong supportive imaging features, such as clear observation of connection between the cyst and the main pancreatic duct or multiplicity of branch-duct cysts.
Statistical analyses were performed using the Fisher exact test (2-sided) for categorical data and the Student t test (2-sided) for continuous data. The a value for both tests was set at .05.
RESULTS
The study cohort consisted of 113 PCF samples from 105 patients (51% women) with a median age of 68 years (Table 1) . Eighty-one (71.7%) samples were adequate for cytology, 31 (27.4%) were limited, and only 1 (0.9%) was unsatisfactory. Twenty-one (18.6%) of the cysts reviewed had high-grade cytologic atypia, and 51 (45.1%) had evidence of mucinous cytology (acellular mucin, mucinous epithelium, and/or a CEA level >192 ng/mL). When KRAS and GNAS variants were included as additional evidence of mucinous origin, the number of mucinous cysts increased to 71 (62.8%) ( Table 2 ). The median CEA and amylase values were 53.6 ng/mL and 16,500 U/L, respectively, and the mean values were 4027 ng/mL and 46,440 U/L, respectively.
NGS was positive for a significant variant in 67 samples (59.3%), for a total of 119 variants ( Table 3 ). The majority of variants were KRAS (n 5 68 in 60 cases) or GNAS (n 5 30 in 27 cases) (Fig. 2) , supporting a mucinous etiology in 65 samples, of which 20 lacked other evidence of a mucinous neoplasm. Other variants observed included cyclin-dependent kinase inhibitor 2A (CDKN2A) (n 5 10; 14.9%), tumor protein 53 (TP53) (n 5 5; 7.5%), SMAD family member 4 (SMAD4) (n 5 2; 3.0%), as well as the von Hippel-Lindau tumor suppressor (VHL), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF), notch 1 (NOTCH1), and phosphatidylinositol-4,5-bisphosphate 3 kinase catalytic subunit a (PIK3CA) (n 5 1; 1.5% each) (Fig. 2) . Twenty-five patients (23.8%) had surgical pathology follow-up, which, when combined with definitive followup cytology or unequivocal clinical findings, resulted in a total of 38 specimens from 37 patients (35.2%) with a substantiated diagnosis (Table 1) . Of these, 8 were nonmucinous cysts, 6 were IPMNs, and 24 were cancerous cysts (either frank carcinoma or IPMNs with high-grade dysplasia) (Table 4 ). There were no significant differences in age or sex between the groups (patients with cancerous cysts tended to be older than those with nonmucinous cysts, although the difference did not reach statistical significance). Sex ratios did not differ significantly between the groups (although patients with cancerous cysts tended to be male). No cysts in the IPMN or nonmucinous groups had HGA, although 75% of cysts in patients with cancer did (P < .001 vs nonmucinous cysts; P 5 .002 vs IPMNs). Mucinous cytologic characteristics (mucinous epithelium, acellular mucin, or CEA >192 ng/mL) were present in 12.5% of nonmucinous cysts, 50% of IPMNs, and 75% of cancerous cysts (P 5 .003 between nonmucinous and cancerous cysts; others were nonsignificant). When KRAS or GNAS variants were included as support of mucinous etiology, 12.5% of nonmucinous lesions, 100% of IPMNs, and 88% of cancerous lesions were classified as mucinous cysts (P 5 .005 between nonmucinous cysts and IPMNs; P < .001 between nonmucinous and cancerous cysts). Cyst amylase levels were not different between the 3 categories, but CEA levels were significantly higher in the cancer group compared with the benign group (P 5 .04; others were nonsignificant). Positive NGS results were significantly more common in IPMNs and cancer than in nonmucinous cysts (P 5 .005 and P 5 .002, respectively). In addition, the mutation rate in IPMNs and cancerous cysts was greater than the rate in nonmucinous cysts (P 5 .03 and P < .001, respectively). However, there was no significant difference in positive NGS results or in the mutation rate between cancerous cysts and IPMNs. Although KRAS variants were significantly more common in the IPMN and cancer groups than in the benign group (P 5 .005 and P 5 .003, respectively), the difference did not reach significance with any other single gene. However, pooled non-KRAS, non-GNAS variants (including TP53, SMAD4, CDKN2A, and NOTCH1) were significantly more common in cancerous cysts compared with nonmucinous cysts (P 5 .03) and approached but did not reach statistical significance compared with IPMNs (P 5 .06).
The presence of a KRAS variant had 80% sensitivity and 88% specificity for mucinous etiology (IPMN or carcinoma), whereas a GNAS variant had 27% sensitivity but 100% specificity (Table 5 ). In comparison, mucinous cytology and CEA analysis had 70% sensitivity and 88% specificity for mucinous lesions. The combination of cytology, CEA, and NGS had 90% sensitivity and 88% specificity for mucinous lesions. HGA on cytology was associated with 75% sensitivity and 100% specificity for cancer. The addition of non-KRAS/GNAS variants to cytology improved the sensitivity to 79%, and specificity remained at 100%. Abbreviations: CEA, carcinoembryonic antigen; CI, confidence interval; GNAS, guanine nucleotide-binding protein; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NGS, next-generation sequencing.
DISCUSSION
The preoperative diagnosis of pancreatic cystic lesions is a serious diagnostic issue considering the incidence of these lesions, difficulty of sampling, potential lethality of their underlying pathology, morbidity of treatment, and difficulty of cytopathologic diagnosis. These cysts range from totally benign (e.g., pseudocysts and serous cystadenomas), requiring minimal to no follow-up, to premalignant lesions (e.g., IPMNs), requiring closer follow-up because of their potential to progress to malignancy, to carcinoma, which requires surgical intervention. Currently, determining which IPMNs need surgical resection is a management conundrum, because most branch-duct IPMNs are low risk, and many patients are elderly and have comorbid conditions that render surgery riskier than conservative management with observation. Cytology is currently the best test for determining early progression to malignancy, but the sensitivity and specificity of cytology are still modest at approximately 85%. 10, 22 Molecular analysis, particularly NGS, is ideal for evaluating these samples and providing diagnostic support to cytologic analysis. Because cyst fluid often can be paucicellular and the cellular elements should be triaged to microscopy, an ideal test can be run on cell-free cyst fluid, requires a minimal volume, should be easily scalable to deal with increasing demand for this sampling procedure, and be relatively low cost given current economic constraints. Given these conditions, we decided to use the MGH anchored multiplex PCR platform, which covers exons of 39 known oncogenes. This test fits the above requirements and allows us to query numerous genes that are frequently mutated in pancreatic neoplasms.
Mucinous etiology, defined by cytology (including grossly mucinous fluid, mucinous epithelium, or acellular mucin), chemistry (defined by CEA > 192 ng/mL), and NGS (defined as positive KRAS or GNAS variant), was better at differentiating nonmucinous from mucinous cysts than NGS, which only differentiated nonmucinous from cancerous cysts (and not from IPMNs); and this can have a significant impact on the clinical impression from imaging studies and, thus, patient management. 4 The addition of NGS to cytology increased the prevalence of mucinous cysts from 45.1% to 62.8% (a 39.2% increase). It also improved the correct rate of diagnosis for IPMNs as mucinous (requiring additional follow-up) from 50% to 100% in resection specimens. This correlated to an increased sensitivity from 70% to 90%. The addition of NGS did not increase the specificity for mucinous lesions (87.5% for both modalities). KRAS and GNAS alone had specificities of 88% and 100%, respectively, for mucinous lesions, but the sensitivities were 80% and 27%, respectively. Compared with mucinous cysts, nonmucinous cysts had a lower rate of mutation and had lower absolute numbers of variants detected. This supports the common knowledge that mucinous cysts and carcinomas are frequently associated with (often multiple) variants (commonly in KRAS and GNAS), whereas nonmucinous cysts are not. 23 Variants in KRAS and GNAS support a mucinous neoplasm, and GNAS is 100% specific. The presence of a KRAS variant in a single, nonmucinous cyst may have been caused by a low-grade pancreatic intraepithelial lesion associated with chronic pancreatitis and benign ductal stenosis that mimicked a main-duct IPMN on imaging. Non-KRAS/GNAS variants in the outcomes cohort, which, in this case, included TP53 (n 5 4; 10.5%), SMAD4 (n 5 2; 5.3%), CDKN2A (n 5 8; 21.1%), and NOTCH1 (n 5 1; 2.6%), were exclusively associated with carcinoma. This is likely because of the secondary accumulation of late mutations as a cystic lesion underwent malignant progression. This finding alone had a sensitivity of 45.8% and a specificity of 100% for carcinoma in the current cohort. HGA on cytology had a sensitivity of 75% and a specificity of 100% for carcinoma. Although cytology was more sensitive for the detection of carcinoma, the criteria for high-grade cytologic atypia and the standardized reporting terminology for pancreatic cysts has only recently been reported. 9, 24 Thus, as the coverage of NGS for different variants expands, likely so will the sensitivity. The presence of cytologic HGA or non-KRAS/GNAS variants indicates a high-risk cyst that requires additional intervention, whether it is biopsy or surgery.
Limitations of this study include the relatively small numbers of patients who actually underwent resection and the finding that those with adequate diagnoses tended to have cancer (who underwent resection more frequently and had more specific clinical-radiographic findings). In addition, we only considered cases for which NGS analysis was successful, which may have biased the population to more patients who had cellular lesions or lesions that readily shed DNA. However, despite these limitations, we believe that this study strongly supports the use of NGS for delineating mucinous cyst etiology, as well as providing additional support of late mutations indicating higher genetic risk in pancreatic cysts.
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